Workboat Indexes

Otsuka Holdings Co. Ltd (OP: OTSKF )

63.85 UNCHANGED

Streaming Delayed Price Updated: 9:30 AM EST, Nov 13, 2024 Add to My Watchlist

Price and Volume

Volume	0
Open	63.85
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	63.85
Today's Range	63.85 - 63.85
52wk Range	35.91 - 66.15
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation

April 16, 2024

IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.

Via Benzinga

Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo

March 20, 2024

IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed.

Via Benzinga

Performance

YTD	+77.81%	+77.81%
1 Month	+1.75%	+1.75%
3 Month	+1.75%	+1.75%
6 Month	N/A	N/A
1 Year	+63.09%	+63.09%

More News

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More

September 05, 2023

Via Benzinga

Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions

August 31, 2023

Via Benzinga

Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension

August 24, 2023

Via Benzinga

Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device

August 23, 2023

Via Benzinga

Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation

May 11, 2023

Via Benzinga

Psychedelics Management Updates: Two Top Companies Appoint New CEOs, Here's What We Know

July 19, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

July 01, 2022

Via Benzinga

Five Companies Developing Second Generation Psychedelics For Mental Health

March 24, 2022

Via Benzinga

1906 New Highs Leverages Cannabis 3.0 to Give Consumers Safer and More Effective Aids for Sleep, Anxiety, Mood, and Focus

October 11, 2021

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.